当前位置： SCI文献检索 > Molecular Oncology期刊下所有文献 > The interaction of PKN3 with RhoC promotes malignant growth.

The interaction of PKN3 with RhoC promotes malignant growth.

Abstract：

:PKN3 is an AGC-family protein kinase implicated in growth of metastatic prostate cancer cells with phosphoinositide 3-kinase pathway deregulation. The molecular mechanism, however, by which PKN3 contributes to malignant growth and tumorigenesis is not well understood. Using orthotopic mouse tumor models, we now show that inducible knockdown of PKN3 protein not only blocks metastasis, but also impairs primary prostate and breast tumor growth. Correspondingly, overexpression of exogenous PKN3 in breast cancer cells further increases their malignant behavior and invasiveness in-vitro. Mechanistically, we demonstrate that PKN3 physically interacts with Rho-family GTPases, and preferentially with RhoC, a known mediator of tumor invasion and metastasis in epithelial cancers. Likewise, RhoC predominantly associates with PKN3 compared to its closely related PKN family members. Unlike the majority of Rho GTPases and PKN molecules, which are ubiquitously expressed, both PKN3 and RhoC show limited expression in normal tissues and become upregulated in late-stage malignancies. Since PKN3 catalytic activity is increased in the presence of Rho GTPases, the co-expression and preferential interaction of PKN3 and RhoC in tumor cells are functionally relevant. Our findings provide novel insight into the regulation and function of PKN3 and suggest that the PKN3-RhoC complex represents an attractive therapeutic target in late-stage malignancies.

journal_name

Mol Oncol

journal_title

Molecular oncology

authors

Unsal-Kacmaz K,Ragunathan S,Rosfjord E,Dann S,Upeslacis E,Grillo M,Hernandez R,Mack F,Klippel A

doi

10.1016/j.molonc.2011.12.001

subject

Has Abstract

pub_date

2012-06-01 00:00:00

pages

284-98

issue

3

eissn

1574-7891

issn

1878-0261

pii

S1574-7891(11)00147-5

journal_volume

6

pub_type

杂志文章

相关文献

Molecular Oncology文献大全
  • Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients.

    abstract：:Most solid tumors, including colorectal cancers, shed cell-free DNA (ctDNA) in the blood. ctDNA can be analyzed to generate molecular profiles which capture the heterogeneity of the disease more comprehensively then tumor tissue biopsies. This approach commonly called 'liquid biopsy' can be applied to monitor response...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2015.12.005

    authors： Siravegna G,Bardelli A

    更新日期：2016-03-01 00:00:00

  • Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.

    abstract：:Resistance to chemotherapy is a serious problem for the successful treatment of ovarian cancer patients but signalling pathways that contribute to this chemoinsensitivity are largely unknown. We demonstrate that the chemotherapeutic drug doxorubicin induces activation of the HER3-PI3K-AKT signalling cascade in ovarian...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2012.07.001

    authors： Bezler M,Hengstler JG,Ullrich A

    更新日期：2012-10-01 00:00:00

  • Glycan-related gene expression signatures in breast cancer subtypes; relation to survival.

    abstract：:Alterations in glycan structures are early signs of malignancy and have recently been proposed to be in part a driving force behind malignant transformation. Here, we explore whether differences in expression of genes related to the process of glycosylation exist between breast carcinoma subtypes - and look for their ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.12.013

    authors： Potapenko IO,Lüders T,Russnes HG,Helland Å,Sørlie T,Kristensen VN,Nord S,Lingjærde OC,Børresen-Dale AL,Haakensen VD

    更新日期：2015-04-01 00:00:00

  • Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF.

    abstract：:The small heat-shock protein of 27 kDa (HSP27) is highly expressed in many cancers and is associated with aggressive tumour behaviour, metastasis, poor prognosis and resistance to chemotherapy. We aimed at assessing the role of HSP27 in modulating responses to target therapies. We selected several oncogene-addicted ca...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12042

    authors： Konda JD,Olivero M,Musiani D,Lamba S,Di Renzo MF

    更新日期：2017-06-01 00:00:00

  • The epigenetics of breast cancer.

    abstract：:Epigenetic changes can be defined as stable molecular alterations of a cellular phenotype such as the gene expression profile of a cell that are heritable during somatic cell divisions (and sometimes germ line transmissions) but do not involve changes of the DNA sequence itself. Epigenetic phenomena are mediated by se...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2010.04.002

    authors： Jovanovic J,Rønneberg JA,Tost J,Kristensen V

    更新日期：2010-06-01 00:00:00

  • MiR-195 and miR-497 suppress tumorigenesis in lung cancer by inhibiting SMURF2-induced TGF-β receptor I ubiquitination.

    abstract：:SMURF2 is a member of the HECT family of E3 ubiquitin ligases that have important roles as a negative regulator of transforming growth factor-β (TGF-β) signaling through ubiquitin-mediated degradation of TGF-β receptor I. However, the regulatory mechanism of SMURF2 is largely unknown. In this study, we identified that...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12581

    authors： Chae DK,Park J,Cho M,Ban E,Jang M,Yoo YS,Kim EE,Baik JH,Song EJ

    更新日期：2019-12-01 00:00:00

  • Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.

    abstract：:ATR-CHEK1 signalling is critical for genomic stability. ATR-CHEK1 signalling may be deregulated in breast cancer and have prognostic, predictive and therapeutic significance. We investigated ATR, CHEK1 and phosphorylated CHEK1 (Ser345) protein (pCHEK1) levels in 1712 breast cancers. ATR and CHEK1 mRNA expression was e...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.10.013

    authors： Abdel-Fatah TM,Middleton FK,Arora A,Agarwal D,Chen T,Moseley PM,Perry C,Doherty R,Chan S,Green AR,Rakha E,Ball G,Ellis IO,Curtin NJ,Madhusudan S

    更新日期：2015-03-01 00:00:00

  • Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.

    abstract：:Although mutations in the phosphoinositide 3-kinase catalytic subunit (PIK3CA) are common in breast cancer, PI3K inhibitors alone have shown modest efficacy. We sought to identify additional pathways altered in PIK3CA-mutant tumors that might be targeted in combination with PI3K inhibitors. We generated two transgenic...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12053

    authors： Merino VF,Cho S,Liang X,Park S,Jin K,Chen Q,Pan D,Zahnow CA,Rein AR,Sukumar S

    更新日期：2017-05-01 00:00:00

  • Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?

    abstract：:Histone methyltransferases (HMTs) catalyze the methylation of lysine and arginine residues on histone tails and non-histone targets. These important post-translational modifications are exquisitely regulated and affect chromatin compaction and transcriptional programs leading to diverse biological outcomes. There is a...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2016.09.003

    authors： Michalak EM,Visvader JE

    更新日期：2016-12-01 00:00:00

  • Methylation-associated miR-193b silencing activates master drivers of aggressive prostate cancer.

    abstract：:Epigenetic silencing of miRNA is a primary mechanism of aberrant miRNA expression in cancer, and hypermethylation of miRNA promoters has been reported to contribute to prostate cancer initiation and progression. Recent data have shown that the miR-193b promoter is hypermethylated in prostate cancer compared with norma...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12536

    authors： Mazzu YZ,Yoshikawa Y,Nandakumar S,Chakraborty G,Armenia J,Jehane LE,Lee GM,Kantoff PW

    更新日期：2019-09-01 00:00:00

  • Honokiol confers immunogenicity by dictating calreticulin exposure, activating ER stress and inhibiting epithelial-to-mesenchymal transition.

    abstract：:Peritoneal dissemination is a major clinical obstacle in gastrointestinal cancer therapy, and it accounts for the majority of cancer-related mortality. Calreticulin (CRT) is over-expressed in gastric tumors and has been linked to poor prognosis. In this study, immunohistochemistry studies revealed that the up-regulati...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.12.009

    authors： Liu SH,Lee WJ,Lai DW,Wu SM,Liu CY,Tien HR,Chiu CS,Peng YC,Jan YJ,Chao TH,Pan HC,Sheu ML

    更新日期：2015-04-01 00:00:00

  • Expression patterns of bone morphogenetic protein antagonists in colorectal cancer desmoplastic invasion fronts.

    abstract：:Bone morphogenetic proteins (BMPs) are a group of growth factors with dual functions in cancer development and progression. Recently, certain tumor-promoting roles have been identified for selected antagonists/inhibitors (BMPIs) of this developmental pathway. A recent focus on the implication of BMP in colorectal canc...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.04.004

    authors： Karagiannis GS,Treacy A,Messenger D,Grin A,Kirsch R,Riddell RH,Diamandis EP

    更新日期：2014-10-01 00:00:00

  • Tackling the cancer burden: the economic impact of primary prevention policies.

    abstract：:Cancer is a noncommunicable disease (NCD) with increasing incidence and therefore constitutes a major public health issue. To reduce the health and economic burden of cancer, policy-makers across the world have implemented a range of preventative interventions targeting risk factors with a known link to the disease. I...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12812

    authors： Cheatley J,Aldea A,Lerouge A,Devaux M,Vuik S,Cecchini M

    更新日期：2020-10-05 00:00:00

  • Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells.

    abstract：:Platinum-based compounds remain a well-established chemotherapy for cancer treatment despite their adverse effects which substantially restrict the therapeutic windows of the drugs. Both the cell type-specific toxicity and the clinical responsiveness of tumors have been associated with mechanisms that alter drug entry...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12648

    authors： Melnikova M,Wauer US,Mendus D,Hilger RA,Oliver TG,Mercer K,Gohlke BO,Erdmann K,Niederacher D,Neubauer H,Buderath P,Wimberger P,Kuhlmann JD,Thomale J

    更新日期：2020-04-01 00:00:00

  • The brain acid-soluble protein 1 (BASP1) interferes with the oncogenic capacity of MYC and its binding to calmodulin.

    abstract：:The MYC protein is a transcription factor with oncogenic potential controlling fundamental cellular processes such as cell proliferation, metabolism, differentiation, and apoptosis. The MYC gene is a major cancer driver, and elevated MYC protein levels are a hallmark of most human cancers. We have previously shown tha...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12636

    authors： Hartl M,Puglisi K,Nist A,Raffeiner P,Bister K

    更新日期：2020-03-01 00:00:00

  • c-MYB- and PGC1a-dependent metabolic switch induced by MYBBP1A loss in renal cancer.

    abstract：:The tumor microenvironment may alter the original tumorigenic potential of tumor cells. Under harsh environmental conditions, genetic alterations conferring selective advantages may initiate the growth of tumor subclones, providing new opportunities for these tumors to grow. We performed a genetic loss-of-function scr...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12499

    authors： Felipe-Abrio B,Verdugo-Sivianes EM,Carnero A

    更新日期：2019-07-01 00:00:00

  • SPT6 recruits SND1 to co-activate human telomerase reverse transcriptase to promote colon cancer progression.

    abstract：:Human telomerase reverse transcriptase (hTERT) plays an extremely important role in cancer initiation and development, including colorectal cancer (CRC). However, the precise upstream regulatory mechanisms of hTERT in different cancer types remain poorly understood. Here, we uncovered the candidate transcriptional fac...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12878

    authors： Diao C,Guo P,Yang W,Sun Y,Liao Y,Yan Y,Zhao A,Cai X,Hao J,Hu S,Yu W,Chen M,Wang R,Li W,Zuo Y,Pan J,Hua C,Lu X,Fan W,Zheng Z,Deng W,Luo G,Guo W

    更新日期：2020-12-11 00:00:00

  • Mining cancer gene expression databases for latent information on intronic microRNAs.

    abstract：:Around 50% of all human microRNAs reside within introns of coding genes and are usually co-transcribed. Gene expression datasets, therefore, should contain a wealth of miRNA-relevant latent information, exploitable for many basic and translational research aims. The present study was undertaken to investigate this pos...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.10.001

    authors： Monterisi S,D'Ario G,Dama E,Rotmensz N,Confalonieri S,Tordonato C,Troglio F,Bertalot G,Maisonneuve P,Viale G,Nicassio F,Vecchi M,Di Fiore PP,Bianchi F

    更新日期：2015-02-01 00:00:00

  • Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.

    abstract：:Our limited understanding of the biological impact of the whole spectrum of early breast lesions together with a lack of accurate molecular-based risk criteria for the diagnosis and assignment of prognostic significance to biopsy findings presents an important problem in the clinical management of patients harboring p...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2010.09.005

    authors： Moreira JM,Cabezón T,Gromova I,Gromov P,Timmermans-Wielenga V,Machado I,Llombart-Bosch A,Kroman N,Rank F,Celis JE

    更新日期：2010-12-01 00:00:00

  • Allo-reactive T cells for the treatment of hematological malignancies.

    abstract：:Several mechanisms can be responsible for control of hematological tumors by allo-reactive T cells. Following allogeneic stem cell transplantation (alloSCT) donor T cells recognizing genetic disparities presented on recipient cells and not on donor cells are main effectors of tumor control, but also of the detrimental...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2015.10.014

    authors： Falkenburg JH,Jedema I

    更新日期：2015-12-01 00:00:00

  • Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma.

    abstract：:Protein inhibitor of activated STAT3 (PIAS3) is an endogenous suppressor of signal transducer and activator of transcription 3 (STAT3) signaling. By directly interacting with phosphorylated STAT3, PIAS3 can block the downstream transcriptional activity of STAT3, which is hyper-activated in various cancers. We previous...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12386

    authors： He T,McColl K,Sakre N,Chen Y,Wildey G,Dowlati A

    更新日期：2018-12-01 00:00:00

  • APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma - characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing.

    abstract：:Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1 or APE1) is a multifunctional protein that regulates numerous transcription factors associated with cancer-related pathways. Because APE1 is essential for cell viability, generation of APE1-knockout cell lines and determining a comprehensive list of genes...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12138

    authors： Shah F,Goossens E,Atallah NM,Grimard M,Kelley MR,Fishel ML

    更新日期：2017-12-01 00:00:00

  • miRNAs as radio-response biomarkers for breast cancer stem cells.

    abstract：:In breast cancer (BC), the presence of cancer stem cells (CSCs) has been related to relapse, metastasis, and radioresistance. Radiotherapy (RT) is an extended BC treatment, but is not always effective. CSCs have several mechanisms of radioresistance in place, and some miRNAs are involved in the cellular response to io...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12635

    authors： Griñán-Lisón C,Olivares-Urbano MA,Jiménez G,López-Ruiz E,Del Val C,Morata-Tarifa C,Entrena JM,González-Ramírez AR,Boulaiz H,Zurita Herrera M,Núñez MI,Marchal JA

    更新日期：2020-03-01 00:00:00

  • PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells.

    abstract：:Triple negative breast cancer (TNBC) is a very aggressive subgroup of breast carcinoma, still lacking specific markers for an effective targeted therapy and with a poorer prognosis compared to other breast cancer subtypes. In this study we investigated the possibility that TNBC cells contribute to the establishment of...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.03.015

    authors： Plantamura I,Casalini P,Dugnani E,Sasso M,D'Ippolito E,Tortoreto M,Cacciatore M,Guarnotta C,Ghirelli C,Barajon I,Bianchi F,Triulzi T,Agresti R,Balsari A,Campiglio M,Tripodo C,Iorio MV,Tagliabue E

    更新日期：2014-07-01 00:00:00

  • Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.

    abstract：:Triple-negative breast cancer (TNBC), the most refractory subtype of breast cancer to current treatments, accounts disproportionately for the majority of breast cancer-related deaths. This is largely due to cancer plasticity and the development of cancer stem cells (CSCs). Recently, distinct yet interconvertible mesen...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12167

    authors： Sulaiman A,McGarry S,Li L,Jia D,Ooi S,Addison C,Dimitroulakos J,Arnaout A,Nessim C,Yao Z,Ji G,Song H,Gadde S,Li X,Wang L

    更新日期：2018-04-01 00:00:00

  • Integrative analysis of cancer imaging readouts by networks.

    abstract：:Cancer is a multifactorial and heterogeneous disease. The corresponding complexity appears at multiple levels: from the molecular and the cellular constitution to the macroscopic phenotype, and at the diagnostic and therapeutic management stages. The overall complexity can be approximated to a certain extent, e.g. cha...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2014.08.013

    authors： Dominietto M,Tsinoremas N,Capobianco E

    更新日期：2015-01-01 00:00:00

  • Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.

    abstract：:Pharmacogenomics is the study of genetic factors determining drug response or toxicity. The use of pharmacogenomics is especially desirable in oncology because the therapeutic index of oncology drugs is often narrow, the need for favorable drug response is often acute, and the consequences of drug toxicity can be life...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2012.01.005

    authors： O'Donnell PH,Ratain MJ

    更新日期：2012-04-01 00:00:00

  • Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors.

    abstract：:Targeted therapy for patients with HER2-positive (HER2+) breast cancer has improved overall survival, but many patients still suffer relapse and death from the disease. Intratumor heterogeneity of both estrogen receptor (ER) and HER2 expression has been proposed to play a key role in treatment failure, but little work...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12375

    authors： Rye IH,Trinh A,Saetersdal AB,Nebdal D,Lingjaerde OC,Almendro V,Polyak K,Børresen-Dale AL,Helland Å,Markowetz F,Russnes HG

    更新日期：2018-11-01 00:00:00

  • Altered purinergic receptor-Ca²⁺ signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells.

    abstract：:Hypoxia is a feature of the microenvironment of many cancers and can trigger epithelial-mesenchymal transition (EMT), a process by which cells acquire a more invasive phenotype with enriched survival. A remodeling of adenosine 5'-triphosphate (ATP)-induced Ca(2+) signaling via purinergic receptors is associated with e...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2015.09.006

    authors： Azimi I,Beilby H,Davis FM,Marcial DL,Kenny PA,Thompson EW,Roberts-Thomson SJ,Monteith GR

    更新日期：2016-01-01 00:00:00

  • Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.

    abstract：:Modern technologies enable detection and characterization of circulating tumor cells (CTC) in peripheral blood samples. Thus, CTC have attracted interest as markers for therapeutic response in breast cancer. First studies have incorporated CTC analyses to guide therapeutic interventions and stratification of breast ca...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2016.07.005

    authors： Gasch C,Oldopp T,Mauermann O,Gorges TM,Andreas A,Coith C,Müller V,Fehm T,Janni W,Pantel K,Riethdorf S

    更新日期：2016-10-01 00:00:00